基于网络药理学方法研究丹参-葛根配伍治疗冠心病的作用机制

为探讨丹参-葛根治疗冠心病的作用机制。利用网络药理学,首先在中药系统药理学分析平台获取丹参-葛根活性成分和作用靶点,然后在TTD、DrugBank和Disgenet数据库获取冠心病作用靶点,最后利用网络药理学分析软件及相关数据库进行靶蛋白相互作用网络(PPI)构建、靶点富集分析和活性成分-靶点-通路网络构建。结果显示筛选出61个活性成分和68个共有靶点。GO分析结果显示丹参-葛根参与RNA聚合酶II启动子的转录和炎症等多种生物学过程,靶标主要集中于细胞外空间、质膜和核等部位。KEGG分析结果显示丹参-葛根配伍调节包括HIF-10、PI3K-Akt、TNF和Jak-STAT等信号通路。综上所述,丹参-葛根中的活性成分丹参酮ⅡA、木犀草素和葛根素等通过HIF-10、PI3K-Akt、TNF和Jak-STAT等信号通路对TNF、VEGFA、TP53和IL6等相关靶点发挥血压调节、血管生成和炎症反应等作用。本研究结果为进一步研究丹参-葛根的药理作用提供了参考。     

基于分子对接和系统药理学小青龙汤治疗哮喘的作用机制

为从分子层面阐述小青龙汤治疗哮喘的作用机制,探索小青龙汤的潜在靶标,本研究检索中药系统药理学数据库及分析平台(TCMSP)并根据口服生物利用度(oralbioavailability,OB)、药物相似性(drug-likeness,DL)筛选出小青龙汤的活性成分,利用Pharmmapper数据库筛选小青龙汤潜在作用靶点,挖掘CTD、Genecards数据库以筛选与哮喘相关的作用靶点,利用Cytoscape 3.6.1软件构建小青龙汤的蛋白互作网络图、化合物靶点图,并通过计算拓扑学参数找到小青龙汤中关键的作用靶点和化合物。对小青龙汤对哮喘的作用靶点进行GO分析和KEGG分析。利用iGEMDOCK软件进行分子对接,预测作用靶点和主要化合物的结合度。通过筛选得到小青龙汤活性成分、潜在作用靶点;GO分析得到43个生物学过程、11个细胞组成和9个分子功能;KEGG分析包括PI3K-Akt信号通路、HIF-1信号通路、Wnt信号通路等。初步验证和预测了小青龙汤对治疗哮喘的作用机制,并为进一步深入揭示其作用机制提供参考。     

甘草抗动脉粥样硬化机制的网络药理学研究

利用网络药理学方法探讨甘草在抗动脉粥样硬化中的分子机制。本研究利用中医药系统药理学数据库和分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)分析甘草中的有效活性成分,并获得有效成分的作用靶点。通过Cytoscape软件构建可视化靶点互相作用网络,对网络中的关键靶点进行基因本体(GO)富集分析和KEGG通路富集分析。结果显示甘草中40种有效活性成分的预测靶点共97个,47个靶点与动脉粥样硬化(AS)相关,其中18个是血管保护药物和脂质修饰药物的作用靶点,表明甘草可作为调控AS发展的药物。基于97个预测靶点的GO富集分析,发现甘草可参与多种生物学过程,尤其是应对外源性刺激,以及参与细胞凋亡等过程。通过构建甘草靶点与AS疾病靶点相互作用网络(PPI),确定了AKT1、MAPK3、MAPK1、JUN和CASP3等关键靶点,并对关键靶点进行KEGG富集分析,结果表明甘草主要影响调控细胞增殖、生存以及凋亡的细胞信号转导相关通路,并激活先天免疫相关信号通路,调节炎性细胞因子释放,从而发挥抗动脉粥样硬化作用。甘草具有多成分、多靶点、多途径的作用特点,主要通过PI3K-AKT信号途径、MAPK信号途径、NOD样受体信号通路调控细胞增殖和凋亡,同时发挥免疫调控作用,从而影响动脉粥样硬化的发展,由此可见,甘草可作为动脉粥样硬化疾病治疗的候选中草药。     

基于网络药理学和体外实验探讨附子-干姜抗心肌缺血再灌注损伤的作用机制CSCD

运用网络药理学方法探讨附子-干姜(Aconiti Lateralis Radix Preparata-Zingiberis Rhizoma,AZ)抗心肌缺血再灌注损伤(myocardial ischemia-reperfusion injury,MI/RI)的潜在机制。通过中药系统药理数据库TCMSP筛选AZ的活性成分;Disgenet数据库获得MI/RI靶点;STITCH数据库获得蛋白互作;用DAVID数据库获得GO功能富集与KEGG信号通路并利用Cytoscape 3.8.0进行绘图;细胞实验验证网络药理学预测的结果。结果共获得AZ活性成分16个、治疗靶点171个;作图分析发现AKT1、IL6、TNF为潜在靶点;GO富集分析发现AZ可能通过凋亡、炎症、血管舒张发挥治疗作用;KEGG分析发现AZ可能通过PI3K-AKT信号通路、TNF信号通路、HIF信号通路发挥治疗作用;体外研究发AZ可使缺氧复氧损伤的大鼠血管内皮细胞存活率提高、降低凋亡率、氧化损伤;提高HIF-α、VEGF、eNOS蛋白的表达。附子-干姜激活HIF/VEGF/eNOS信号通路,降低血管内皮细胞氧化损伤、凋亡率发挥抗心肌缺血再灌注损伤的作用。     

基于网络药理学的益母草治疗产后腹痛的潜在分子机制研究

本文通过网络药理学方法探讨益母草治疗产后腹痛的潜在分子机制。首先根据TCMSP数据库和文献挖掘益母草的活性成分,在TCMSP、Swiss Target Prediction、Similarity ensemble approach平台上检索活性成分靶点,在OMIM、GeneCards上检索产后腹痛靶点,得到益母草-产后腹痛交集靶点。利用STRING数据库构建蛋白互作(PPI)网络,接着利用Cytoscape软件对PPI网络进行拓扑分析,并对拓扑分析筛选出的核心靶点进行基因本体论(Gene Ontology,GO)分析和京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路分析。最后利用免疫组化实验验证益母草对流产大鼠模型子宫组织中PGF2αR、MMP9、TIMP1、VEGFA、VEGFR2蛋白表达水平的影响。最终得到益母草活性成分10种,与产后腹痛相关靶点144个;通过PPI网络分析筛选出118个靶点,进一步拓扑分析后得到98个节点;然后对这98个节点进行GO和KEGG注释。GO分析得到1151个生物过程(BP)条目,97个细胞组成(CC)条目,122个分子功能(MF)条目;KEGG分析得到41条通路,主要涉及雌激素、PI3K-Akt、MAPK、HIF-1信号通路等。最后免疫组化实验证明益母草可显著抑制流产模型大鼠子宫组织中PGF2αR、MMP9蛋白上调和TIMP1、VEGFR2蛋白下调。本研究通过网络药理学和免疫组化实验验证,显示益母草治疗产后腹痛是多成分、多靶点、多途径相互作用的结果,为益母草的临床应用提供了一定的理论依据。     

基于网络药理学探讨溪黄草黄酮类成分对酒精性肝病的作用机制

基于网络药理学探讨溪黄草黄酮类成分对酒精性肝病(alcoholic liver disease, ALD)的作用机制。通过文献、PubChem、TCMSP、PharmMapper数据库收集成分及预测靶点,利用UniProt数据库规范靶点。再运用GeneCards数据库获取ALD疾病靶点,并经Venny2.1.0获得交集靶点。蛋白相互作用的PPI网络由STRING数据库构建,接着通过DAVID数据库对交集靶点进行GO功能与KEGG通路富集分析。溪黄草黄酮类成分-靶点-通路的作用网络由Cytoscape3.7.0构建,最后对核心靶点进行分子对接验证。本文共收集溪黄草中12种黄酮类成分,这些成分涉及172个与ALD相关的靶点,筛选24个核心靶点。GO富集显示52条生物过程、24条细胞成分、16条分子功能,主要涉及转录调控、细胞凋亡调节、血管内皮生长因子、NF-κB调节、脂质稳态、DNA损伤凋亡等生物过程;KEGG富集27条通路,主要涉及PI3K/Akt信号、FoxO信号、P53信号等关键通路;分子对接显示HSP90AA1、VEGFA、CCND1核心靶点与活性成分有良好的结合效应。综上,本文揭示溪黄草黄酮类成分作用于多靶点,参与多通路的调控发挥治疗ALD的作用机制,为进一步验证溪黄草黄酮类成分治疗ALD的相关靶点及通路提供依据。     

基于网络药理学和分子对接探讨黄芪治疗病毒性心肌炎的作用机制CSCD

本文基于网络药理学方法探讨黄芪治疗病毒性心肌炎的潜在作用机制。通过TCMSP数据库和疾病数据库,分别检索并筛选得到黄芪治疗病毒性心肌炎的潜在作用靶点,利用Cytoscape 3.7.1构建“黄芪活性成分-病毒性心肌炎-靶点”网络、蛋白互作网络,然后利用R语言进行GO功能和KEGG通路富集分析,并通过Sybyl-X 2.0对重要黄芪活性成分和靶点进行分子对接。结果表明,黄芪活性成分22个,关键靶点97个,共涉及1327个生物学过程,29个细胞组分,66个分子功能及90条信号通路。分子对接结果显示异微凸剑叶莎醇与TP53结合最好。本研究初步探讨了黄芪治疗病毒性心肌炎的潜在作用靶点及重要信号通路,为后续提供了新的思路。     

基于疾病与活性化合物靶点网络构建的异鼠李素抗缺血性神经损伤作用评价与验证研究

基于网络药理学与分子对接探讨异鼠李素对缺血性神经损伤的治疗作用。采用ChEMBL、SwissTargetPrediction、DrugBank、STITCH及BindingDB数据库检索异鼠李素药理学靶点,应用DisGeNET、GenCLiP及CTD数据库检索缺血性神经损伤的疾病靶点,取交集作为异鼠李素对缺血性神经损伤的治疗靶点,并进行表型分析。将交集靶点导入STRING构建蛋白互作网络,使用Network analyser进行拓扑分析,同时应用MODE构建功能模块,并基于ClueGo对功能模块进行分析。之后应用DAVID数据库对治疗靶点进行GO及KEGG富集分析。利用Discovery Studio评价异鼠李素与核心靶点的结合活性,最后建立OGD/R损伤PC12细胞模型,采用MTT和LDH法检测细胞活力,Western blot法对AKT1、IL6和MMP2的表达进行检测。异鼠李素通过50个缺血性神经损伤相关靶点,调控细胞凋亡、转录、蛋白质磷酸化、炎症反应等生物学过程,干预PI3K-AKT信号通路、HIF-1信号通路、雌激素信号通路、肿瘤坏死因子信号通路、FoxO信号通路等多条途径发挥抗缺血性神经损伤的作用。初步阐释异鼠李素治疗缺血性神经损伤的作用,涉及多靶点、多通路,为进一步探究其药理学活性奠定理论基础。     

参苓白术散治疗结直肠癌的网络药理学机制及分子靶点探讨

为探究参苓白术散(Shenling Baizhu powder, SLBZP)治疗结直肠癌的作用机制。运用网络药理学的方法,通过TCMSP数据库收集、筛选SLBZP的活性成分并获得作用靶点,GEO数据库筛选获得CRC患者与健康个体之间的差异表达基因作为CRC的相关靶点。借助Cytoscape软件构建药物成分、疾病靶点网络,Bisogenet构建蛋白质相互作用(PPI)网络,以识别SLBZP作用于CRC的候选靶点。通过基因本体(GO)功能富集京都基因与基因组百科全书(KEGG)通路富集分析核心基因的生物学功能及通路富集情况。Cytoscape软件构建了靶点-途径网络,根据Degree筛选关键靶基因。通过分析得到SLBZP治疗CRC的核心靶点165个,发现核心靶点功能注释与转录因子的活性、蛋白质稳定性调节、泛素蛋白连接酶结合等有关。PI3K-Akt信号通路,PD-L1/PD-1途径,病毒致癌等二十个途径均得到显著的富集。AKT1、TP53、PIK3R1为核心基因,MAPK3、NFKB1、CCND1、MAPK1、RELA、CDKN1A、MYC、STAT3、MDM2、JUN、RB1等是SLBZP网络途径中治疗CRC的关键基因。综上SLBZP对CRC的治疗作用可能与特定的生物学过程及相关途径调节炎性反应、优化肠道菌群结构发挥治疗作用。通过网络药理学分析评估,SLBZP复杂的作用机理及作用靶标得到了进一步的揭示,对CRC治疗意义重大。     

基于网络药理学与分子对接探究黄芩有效成分对酒精性肝病的作用机制及效果验证

通过网络药理学和分子对接技术探究中药黄芩治疗酒精性肝病的作用机制，并通过体外细胞实验验证黄芩有效成分对酒精性肝病的治疗效果。在TCMSP、Swiss ADME和Swiss Target Prediction数据库中检索获得黄芩有效成分及其作用靶点；在GeneCards、OMIM、DisGeNET、TTD和PharmGKB数据库中检索获得酒精性肝病相关的疾病靶点；利用String数据库构建靶点相互作用网络；通过Metascape数据库对关键靶点进行京都基因与基因组百科全书(KEGG)通路富集分析、基因本体(GO)富集分析。采用Cytoscape 3.8.0软件构建黄芩治疗酒精性肝病的“有效成分-靶点-通路”互作网络，并筛选出黄芩有效成分和关键靶点进行分子对接。基于网络药理学和分子对接结果，采用体外细胞实验初步验证预测结果。将黄芩有效成分进行ADME筛选后共获得27个，且这27个有效成分可以通过257个基因靶点对酒精性肝病起到治疗作用，其中关键核心靶点有SRC、AKT1、PIK3R1、STAT3、PIK3CA等。KEGG信号通路富集分析结果显示，黄芩治疗酒精性肝病的主要信号通路包括癌症的途...     

Revealing mechanism of Caulis Sargentodoxae for the treatment of ulcerative colitis based on network pharmacology approach

Objective: The traditional Chinese medicine Caulis Sargentodoxae is widely used in the treatment of ulcerative colitis (UC), but the mechanism remains unknown. The present study aims to reveal its effective components, targets and pathways through network pharmacology and bioinformatics approaches.Materials and methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was used to identify effective components. The ligand-based targets prediction was achieved through SwissTargetPrediction and TargetNet. UC-related targets were identified using Gene Expression Omnibus (GEO) data and DisGeNET. The common targets of disease and components were constructed and analyzed by PPI network. Lastly, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses are used to explain the functions of these common targets. Components-Targets-Pathways network was visualized and analyzed to further reveal the connection between the components and targets.Results: Eight active components and 102 key targets were identified to play an important role in UC. These targets were related to regulation of protein serine/threonine kinase activity, positive regulation of cell motility, response to molecule of bacterial origin, response to toxic substance, ERK1 and ERK2 cascade, peptidyl-tyrosine modification, inositol lipid-mediated signaling, cellular response to drug, regulation of inflammatory response and leukocyte migration. Moreover, HIF-1 signaling pathway and PI3K-Akt signaling pathway were the key targets involved in UC-related signaling pathways.Conclusion: The eight active components of Caulis Sargentodoxae mainly play a therapeutic role for UC through synergistic regulation of HIF-1 signaling pathway and PI3K-Akt signaling pathway.     

基于网络药理学的大黄治疗阿尔茨海默病作用机制研究

基于网络药理学探讨大黄治疗阿尔茨海默病(AD)的作用机制.借助TCMSP数据库及Uniprot数据库筛选出大黄有效成分及靶点基因.通过Drugbank、Dis Ge NET和TTD数据库筛选出阿尔茨海默病的靶点基因;成分靶点与疾病靶点映射后使用Cytoscape 3.7.1软件构建药物有效成分-靶点蛋白相互作用网络,使...     

基于网络药理学探讨丹参-丹皮配伍抗脑缺血损伤的作用机制

本文旨在通过网络药理学和分子对接方法探讨丹参-丹皮活性成分治疗脑卒中的潜在分子机制.首先基于中药系统药理学分析平台筛选丹参、丹皮的活性成分及其作用靶点,利用CTD、TTD和GeneCards数据库收集脑卒中相关靶点.然后将药物和疾病靶点取交集,借助STRING数据库获取靶点间相互作用关系,利用R语言的Cluster-P...     

Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology

Ellagic acid (EA) is a natural polyphenolic compound. Recent studies have shown that EA has potential anticancer properties against gastric cancer (GC). This study aims to reveal the potential targets and mechanisms of EA against GC. This study adopted methods of bioinformatics analysis and network pharmacology, including the weighted gene co-expression network analysis (WGCNA), construction of protein–protein interaction (PPI) network, receiver operating characteristic (ROC) and Kaplan–Meier (KM) survival curve analysis, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, molecular docking and molecular dynamics simulations (MDS). A total of 540 EA targets were obtained. Through WGCNA, we obtained a total of 2914 GC clinical module genes, combined with the disease database for screening, a total of 606 GC-related targets and 79 intersection targets of EA and GC were obtained by constructing Venn diagram. PPI network was constructed to identify 14 core candidate targets; TP53, JUN, CASP3, HSP90AA1, VEGFA, HRAS, CDH1, MAPK3, CDKN1A, SRC, CYCS, BCL2L1 and CDK4 were identified as the key targets of EA regulation of GC by ROC and KM curve analysis. The enrichment analysis of GO and KEGG pathways of key targets was performed, and they were mainly enriched in p53 signalling pathway, PI3K-Akt signalling pathway. The results of molecular docking and MDS showed that EA could effectively bind to 13 key targets to form stable protein–ligand complexes. This study revealed the key targets and molecular mechanisms of EA against GC and provided a theoretical basis for further study of the pharmacological mechanism of EA against GC.     

急性髓系白血病mRNA与非编码RNA差异表达谱及CeRNA调控网络分析

利用GEO数据库(gene expression omnibus database)通过生物信息学分析方法探讨急性髓系白血病(acute myelogenous leukemia,AML)的发病机制。检索GEO数据库中AML相关芯片数据集GSE142698、GSE142699和GSE96535。利用GEO2R分析得到差异mRNAs、miRNAs以及差异lncRNAs。利用在线生物信息学分析工具DAVID对差异mRNAs进行GO富集分析和KEGG通路分析。利用miRWalk数据库预测AML相关miRNAs的靶向mRNAs,利用Spongescan数据库预测AML相关miRNAs的靶向lncRNAs,构建lncRNA-miRNA-mRNA竞争性内源RNA （competing endogenous RNA,ceRNA）调控网络。共筛选出29个显著差异mRNAs、70个显著差异miRNAs和20 005个显著差异lncRNAs。GO富集分析和KEGG通路分析显示,差异表达基因主要涉及蛋白磷酸化、细胞分裂、细胞增殖的负调控、基因表达的正向调节、周期蛋白依赖的丝氨酸/苏氨酸激酶活性的调节等生物过程以及细胞周期、细胞衰老、癌症通路、PI3K-Akt通路等信号通路。将miRWalk数据库预测的靶向mRNAs与差异mRNAs取交集,Spongescan数据库预测的靶向lncRNAs与差异lncRNAs取交集,分别确定了25个mRNAs、6个lncRNAs参与AML相关ceRNA调控网络的构建。结果表明,lncRNAs可能作为关键的ceRNA,通过调控miRNA和相关靶基因参与AML的发生与发展,研究结果为AML诊断和治疗的分子生物学研究提供了新的依据。     

Bioactive constituents and the molecular mechanism of Curcumae Rhizoma in the treatment of primary dysmenorrhea based on network pharmacology and molecular docking

BackgroundCurcumae Rhizoma (CR) has a clinical efficacy in activating blood circulation to dissipate blood stasis and has been used for the clinical treatment of qi stagnation and blood stasis (QSBS) primary dysmenorrhea for many years. However, its molecular mechanism is unknown.ObjectiveThe present study aimed to demonstrate the multicomponent, multitarget and multipathway regulatory molecular mechanisms of CR in the treatment of QSBS primary dysmenorrhea.MethodsObservations of pathological changes in uterine tissues and biochemical assays were used to confirm that a rat model was successfully established and that CR was effective in the treatment of QSBS primary dysmenorrhea. The main active components of CR in rat plasma were identified and screened by ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UPLC-Q/TOF-MS). The component-target-disease network and protein-protein interaction (PPI) network of CR were constructed by a network pharmacology approach. Then, we performed Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Molecular docking was adopted to verify the interactions between the core components and targets of CR to confirm the accuracy of the network pharmacology prediction results. Furthermore, we evaluated the bioactive constituents of CR and molecular mechanism of by which CR promote blood circulation and remove blood stasis via platelet tests in vivo and in vitro and Western blot analysis.ResultsThe results of HE staining and biochemical assays of PGF2α, TXB2 and Ca²⁺ showed that CR was effective in the treatment of QSBS primary dysmenorrhea. A total of 36 active components were identified in CR, and 329 common targets were obtained and used to construct the networks. Of these, 14 core components and 10 core targets of CR in the treatment of primary dysmenorrhea were identified. The GO and KEGG enrichment analyses revealed that the common targets were involved in multiple signaling pathways, including the calcium, cAMP, MAPK, and PI3K-Akt signaling pathways, as well as platelet activation, which is closely related to platelet aggregation. The molecular docking results showed that the 14 core components and 10 core targets could bind spontaneously. Two core targets (MAPK1 and CCR5) and 7 core components (Isoprocurcumenol, Curcumadione, Epiprocurcumenol, (+)-Curdione, Neocurdione, Procurcumenol, and 13-Hydroxygermacrone) were closely related to CR in the treatment of primary dysmenorrhea. Furthermore, the in vivo platelet test showed that CR clearly inhibited platelet aggregation. Five core components ((+)-Curdione, Neocurdione, Isoprocurcumenol, Curcumadione and Procurcumenol) obviously inhibited platelet aggregation in vitro. In addition, based on the relationships among the signaling pathways, we confirmed that CR can effectively inhibit the expression of MAPK and PI3K-Akt signaling pathway-related proteins and decrease the protein expression levels of ERK, JNK, MAPK, PI3K, AKT and CCR5, thereby inhibiting platelet aggregation.ConclusionThis study demonstrated the bioactive constituents and mechanisms of CR in promoting blood circulation and removing blood stasis and its multicomponent, multitarget and multipathway treatment characteristics in primary dysmenorrhea. The results provide theoretical evidence for the development and utilization of CR.